Abstract
Objective To observe lamivudine, adefovir dipivoxil montherapy or combined therapy for hepatitis B patients with decompensated cirrhosis. Methods 96 cases of hepatitis B patients with decompensated cirrhosis were ran domly divided into 3 groups, all the patients were given basic treatment, then patients were respectively given lamivudine 100 mg/d(LAM group) , adefovir dipivoxil 10 mg/d(ADV group), lamivudine combined adefovir dipivoxil (combined group) for 48 weeks. The liver function, HBV DNA, HBeAg negative rate and Child-Pugh score were analysed. Results The ALT, ALB, TBil and Child-Pugh scores were improved after 48 weeks of treatment in 3 groups without death, and there were remarkable difference compared with pretreatment (t = 2.21-20.40, P < 0.05). HBV DNA negative conseration rate in LAM group, ADV group and combined group after 48 weeks' treatment were 53.13%, 43.75%, 81.25% respectively, the rates in LAM group and ADV group were significant lower than that in combined group (x2 = 5.74, 9.40, P< 0.05). HBeAg negative rate in LAM, ADV, combined groups were 15.79%, 9.52%, 40.91% respectively, and the rates in LAM group and ADV group were significant lower than that in combined group (x2 = 4.94, 7.73,F< 0.05), 2 cases of YMDD mutation in LAM group were found. Conclusions Lamivudine and adefovir dipivoxil combined or montherapy can effectively improve the liver function and Child-Pugh score for hepatitis B with decompensated cirrhosis, combined beatment can suppress HBV DNA replication more quickly and effectively, and with less viral mutation. Key words: liver cirrhosis; Hepatitis B; Lamivudine; Adefovir
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.